Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Neoplasm Metastasis 4Ovarian Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Glioma 2Carcinoma, Renal Cell 2von Hippel-Lindau Disease 1Xanthogranuloma, Juvenile 1Wilms Tumor 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

palbociclib 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasm Female × palbociclib × 30 days × Clear all
NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡